SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

: Emerging Challenges in Primary Care 2017 Denver, CO
Activity/Course #:
: 10.14.17PC

: Free
Release/Start Date:
: Oct 14 2017
Expiration Date:
: Oct 14 2017
: Primary Care Medicine
Target Audience:
: Primary Care Providers
: Live EC Primary Care
Estimated Time To Complete CME Activity:
: 7.0 hours
: 7.0 AMA PRA Category I Credit(s)
7.0 AANP Contact hour(s) which includes 3.0 pharmacology hour(s)
Hardware/Software Requirements:

Saturday, October 14, 2017

Doubletree by Hilton Denver
3203 Quebec Street
Denver, CO 80207
(303) 321-3333

Registration Fee
There is no registration fee for this activity.

Special Accommodations

NACE fully complies with the legal requirements of the Americans with Disabilities Act. Any activity registrant who feels s/he may need accommodations based on the impact of a disability should contact NACE to discuss your specific need.

Event Parking

Complimentary self-parking is available at the hotel.

Hotel Guest Rooms

NACE has reserved a sleeping room rate of $109 per night at the Doubletree by Hilton Denver. To reserve your room at this rate call (303) 321-3333 and ask for the NACE room block by September 22, 2017.  

Program Summary

Primary care providers face complex challenges everyday in their busy practices. With rapid changes in medicine, staying informed about new developments can be equally challenging. Our goal in this CME activity is to help you hone your skills in the diagnosis and management of patients with varied conditions you are likely encountering in your practice.

We have recruited a faculty of well-known thought leaders and experienced teachers who, as clinicians themselves, understand the challenges you face every day as a primary care provider. Our faculty will be at your disposal to provide evidence-based science, current treatment guidelines, discuss challenging cases, and provide answers for you that can ultimately lead to better health care for your patients. The presentations will include several interactive cases and discussion sessions to keep you actively learning.

Please join us and become an active participant in this one-day learning community of your peers.

Learning Objectives

At the conclusion of this program, participants should be able to:

1. Describe the role of the kidney in glucose metabolism in health and disease; Review the physiologic effects and clinical efficacy of SGLT-2 therapy in various patient populations; Review emerging data on possible renal and macrovascular effects of evidence-based diabetes treatment options; Integrate the impact of treatment decisions on postprandial hyperglycemia and risk of hypoglycemia.

2. Discuss the role of postprandial hyperglycemia in the pathogenesis of diabetic complications; Incorporate GLP-1 RA therapy into practice to reduce post-prandial hyperglycemia and decrease glycemic variability; Compare GLP-1 RAs for glycemic efficacy and differential impact on postprandial glycemic control; Discuss various GLP-1 RA combination strategies with or as a possible alternative to basal insulin in the diabetic patient not at glycemic target.

3. Describe strategies of care in COPD to improve diagnosis and ongoing symptom assessment; Tailor COPD pharmacotherapy according to current guidelines while incorporating unique patient needs and characteristics; Discuss the appropriate use of inhaled therapies for COPD, including the importance of proper inhaler technique; Collaborate with members of interprofessional health care team for effective chronic disease management.

4. Describe the typical clinical presentation of a patient with possible idiopathic pulmonary fibrosis (IPF); Discuss the diagnostic approach to a patient with suspected IPF; Discuss and contrast the available pharmacotherapeutic options for patients with IPF; Discuss and contrast the available nonpharmacotherapeutic options for patients with IPF.

5. Identify a therapeutic role for dopaminergic augmentation treatment in depression; Employ successful alternative treatments for rosacea; Recognize a highly successful intervention for Schamberg’s disease.

6. Become familiar with the current USPSTF recommendations on lung cancer screening; Recognize the risks and benefits of screening for lung cancer; Engage appropriate patients in the lung cancer screening process.



7:30-8:00   Continental Breakfast and Registration
8:00-8:10   Welcome Remarks
Gregg Sherman, MD

Integrating Data on Macrovascular and Microvascular Outcomes into Diabetes Management: Evolving Treatment Strategies
Richard Pratley, MD


GLP-1 Receptor Agonists: New Insights and New Strategies for Successful Long-Term Diabetes Management
Richard Pratley, MD

10:30-10:50   Break
10:50-12:00   The Evolving Landscape of COPD: Strategies to Optimize Care and Improve Outcomes
Franck Rahaghi, MD, MHS, FCCP

Lunch (on your own)

1:00-2:10   Idiopathic Pulmonary Fibrosis: Defining the Role of the Primary Care Clinician in Diagnosis and Therapy
Franck Rahaghi, MD, MHS, FCCP

5 Things I Wish I knew Last Year – A Collection of Clinical Pearls You Can Put Into Practice Immediately
Louis Kuritzky, MD

 3:20-3:30 Break
 3:30-4:40 Lung Cancer Screening: Who, When, Why or Why Not?
Louis Kuritzky, MD

Program Summary and Closing Remarks
Gregg Sherman, MD

 *Agenda subject to change.


Louis Kuritzky, MD
Clinical Assistant Professor Emeritus
Department of Community Health and Family Medicine
University of Florida
Gainesville, FL

Richard Pratley, MD
Senior Investigator and Diabetes Program Head
Translational Research Institute for Metabolism and Diabetes
Research and Education Director, Florida Hospital Diabetes Institute
Orlando, FL

Franck Rahaghi, MD, MHS, FCCP
Director of Advanced Lung Disease Clinic
Director, Pulmonary Hypertension Clinic
Head of Alpha-1 Foundation Clinical Resource Center
Chairman, Dept. of Pulmonary and Critical Care
Cleveland Clinic Florida
Weston, FL

Planning Committee

Gregg Sherman, MD
Chief Medical Officer/Course Director
National Association for Continuing Education
Plantation, FL

Sheila Lucas, CWEP
Activity Director
National Association for Continuing Education
Plantation, FL

Michelle Frisch, MPH, CHCP
National Association for Continuing Education
Plantation, FL

Cassandra A. McCullough, MBA
Chief Executive Officer
Association of Black Cardiologists
New York, NY

Harvey C. Parker, Ph.D., CHCP
National Association for Continuing Education
Plantation, FL

Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 7.0 contact hours of continuing education (which includes 3.0 pharmacology hours).
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the accredited providers are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosure will be provided in the activity materials.
Commercial Support
Emerging Challenges in Primary Care: 2017 is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.; and an independent medical educational grant from Sunovion Pharmaceuticals, Inc.